Andere Sprachen 60 Degrees Pharmaceuticals, Inc.

Aktien

A3END4

US83006G1040

SXTP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.06.2024			% 5 Tage	% 1. Jan.
0.2649 ^USD	-5.49%		-0.97%	-74.03%

30.05.	60 Degrees Pharmaceuticals, Inc. schließt eine Vereinbarung mit dem Tufts Medical Center in Boston zur Durchführung der ersten klinischen Studie mit Tafenoquin zur Behandlung von Babesiose-Patienten	CI
20.05.	60 Degrees Pharmaceuticals finanziert Babesia spp-Tests bei Patientenproben mit chronischer Müdigkeit in einer Studie des NC State College of Veterinary Medicine	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis	11.06.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind	30.05.
60 Degrees Pharmaceuticals, Inc. Enters into an Agreement with Tufts Medical Center in Boston to Conduct the First Clinical Trial of Tafenoquine in Treating Human Babesiosis Patients	30.05.
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20.05.
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study	20.05.
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results	15.05.
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases	08.05.
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02.05.
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required	02.05.
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis	03.04.
60 Degrees Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01.04.
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14.03.
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024	14.03.
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris	20.02.
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer	08.02.
60 Degrees Pharmaceuticals, Inc. Appoints Kristen Landon as Chief Commercial Officer	08.02.
60 Degrees Pharmaceuticals Closes $2.4 Million Public Offering	31.01.
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering	31.01.
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering	31.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen 60 Degrees Pharmaceuticals, Inc.

Aktien

A3END4

US83006G1040

SXTP

Andere Sprachen

Filter